N-glycosylation profile analysis of Trastuzumab biosimilar candidates by Normal Phase Liquid Chromatography and MALDI-TOF MS approaches by Sanchez-De Melo, Ivan et al.
J O U R N A L O F P R O T E O M I C S 1 2 7 ( 2 0 1 5 ) 2 2 5 – 2 3 3
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com/ loca te / j p ro tN-glycosylation profile analysis of Trastuzumab
biosimilar candidates by Normal Phase Liquid
Chromatography and MALDI-TOF MS approaches☆Ivan Sanchez-De Meloa, Paola Grassib, Francisco Ochoaa, Jorge Bolivara,
Francisco J. García-Cózara, Ma Carmen Durán-Ruiza,⁎
aBiotechnology, Biomedicine and Public Health Department, Cadiz University, Spain
bBiopolymer Mass Spectrometry Group, Imperial College, London UKA R T I C L E I N F O☆ This article is part of a Special Issue entit
⁎ Corresponding author at: Biomedicine, Biote
E-mail addresses: ivan.sanchez@uca.es (I
(F. Ochoa), Jorge.bolivar@uca.es (J. Bolivar), c
maricarmen.duran@gm.uca.es (Ma. C. Durán
http://dx.doi.org/10.1016/j.jprot.2015.04.012
1874-3919/© 2015 Elsevier B.V. All rights reseA B S T R A C TAvailable online 21 April 2015 The pharmaceutical market has entered an era in which the production of new therapeutics
is being often replaced by “biosimilars”, copies of already commercialized products waiting
for the patents to expire in order to be distributed in a more competitive and affordable
manners. Due to its relevance, the ErbB2-targeted monoclonal antibody Trastuzumab
(Herceptin) used as breast cancer therapy is one of the main targets in the production of
biosimilars. A major challenge is to produce antibodies with the same or the closest
N-glycosylation pattern seen in the commercialized drug. Several factors, such as growing
conditions or cell types employed, can determine the final composition and structure of the
glycans, significantly affecting the properties of the generated antibodies. Therefore, an
appropriate characterization is essential. In the present study, we describe two different but
complementary strategies to characterize the N-glycosylation of two biosimilar candidates
of Trastuzumab. In the first case, N-glycans are fluorescently labeled and separated by
Normal Phase HPLC. Different sugars will elute at different times and can be identified
using specific oligosaccharide standards. In the second approach, released glycans are
permethylated and analyzed by MALDI-TOF MS, being able to determine the structure
because of the differential sugar masses.
Biological significance
The characterization of the N-glycosylation sites of therapeutic recombinant monoclonal
antibodies (mAbs) is usually one of the most critical and time consuming steps in the
developing process of biosimilars or any other glycosylated drug. Herein we describe two
different but complementary approaches to characterize mAbs glycosylation patterns, the
use of glycan fluorescence labeling coupled to HPLC and MALDI-TOF MS profile analysis.
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tute a major target into the actual biopharmaceutical market
due to their predictable properties, controlled functions and
long circulating life [1]. Murine and chimeric-based mAbs are
being replaced by humanized and fully human mAbs.
More than 30 different mAb-based therapeutics have been
approved for clinical use and many more are currently in
research, development, and pre-clinical stages [2]. It is
estimated that therapeutic mAb and their derivatives account
for almost 36% of the biopharmaceuticals under development
[3]. The total sales of the top selling blockbuster mAbs were
$63 billion in 2013, with the ranks of the top 5 selling mAbs
remaining unchanged from 2012: Humira ($11 billion),
Remicade ($9.7 billion), Rituxan ($7.5 billion), Herceptin
($6.5 billion) and Avastin (6.5 billion) [4]. Currently, Soliris
(eculizumab, Alexion) is the most expensive marketed mAb
with a price of $440,000 per year of treatment. Conversely, due
to the expensiveness of production and characterization of
mAbs, there is huge interest in the development of biosimilars
for the already commercialized innovators, expected to be
released to the market in a more affordable manner once the
patents expire. It has been estimated that by 2019 approxi-
mately 50% of the market will correspond to off-patent
medicines, giving a high market potential for biosimilars.
Both innovative products and biosimilars must achieve high
levels of quality, efficacy and safety before approval. Thus,
biosimilar manufacturers must ensure that their product
conforms as closely as possible to the commercialized one,
reducing the need for expensive clinical trials and time to
reach the market. Therefore, all parties have an interest in
performing comprehensive analysis of their products [1].
Most of the current therapeutic mAbs are humanized or
human IgGs produced as recombinant glycoproteins in
eukaryotic cells (CHO, NS0 and Sp2/0 cells among the most
frequently used). Many alternative production systems and
improved constructs are also being actively investigated [5].
Synthesized IgG molecules are glycosylated at the CH2
domains in the -Fc region, with glycans being covalently
attached at the Asn297 residue [6]. IgG glycans represent on
average only 3% of the total molecule mass. Despite this
low percentage, it is well known the functional relevance of
particular glycoforms on immune effector functions [7],
thermodynamic stability, potential for immunogenicity [8]
and pharmacokinetics [9] of mAbs. In this regard, glycoprotein
analysis is essential within the biopharmaceutical industry,
because the glycan structure can affect the safety and efficacy
of the final products [10]. The actual development of either
innovator or biosimilar mAbs considers the glycosylation
profile as a critical quality attribute (CQA), being a detailed
characterization of mAb glycosylation a key requirement at
the early stages of development. Regulatory authorities
require the glycoform profile to be maintained within strict
limits [6].
Glycosylation depends on multiple factors like the pro-
duction system, selected clonal population and manufac-
turing process, and may be either genetically or chemically
engineered [5]. The biopharmaceutical companies haveachieved the establishment of specific cell lines that can be
expanded in serum- and protein-free media scaled-up to
manufacturing levels while maintaining appropriate glyco-
sylation patterns and minimizing immunogenic glycoforms
[6]. Methods that allow the production of recombinant mAbs
bearing homogeneous oligosaccharides are now becoming
available [11]. In any case, an appropriate validation of the
glycan structures synthesized is crucial. Glycan analysis
represents a major challenge, due to their inherited complex-
ity, lack of chromophore and the existence of various isoforms
(both position and linkage) [10]. According to the European
Medicines Agency's (EMA) guidelines (EMA/CHMP/BMWP/
403543/2010) several orthogonal techniques must be used to
identify and quantify glycoforms, glycosylation profiling and
carbohydrate contents of biosimilar mAbs. Biopharmaceutical
glycosylation profiles are most commonly determined on
glycans released from the protein backbone either chemically
or enzymatically [10]. From this point, several techniques are
applied to elucidate the glycan structures found on mAbs. MS
approaches such as MALDI-TOF MS or ESI–MS can provide
detailed structural information with short analysis times
[12]. MALDI-TOF MS is often used as a first step because its
unique capacity to generate rapidly information about the
nature and diversity of glycans released from native,
recombinant glycoproteins or even more complex biological
samples [13]. Glycan derivatization prior to MS analysis, e.g.
by permethylation, significantly improves the sensitivity of
detection of molecular ions, allows simultaneous analysis of
neutral and sialylated oligosaccharides in the positive ion
mode, and provides predictable fragmentation that gives
characteristic “maps” of fragment ions at each amino sugar
residue [13]. Structural assignments derived from the
MALDI-TOF MS analysis is mainly based on monosaccharide
composition, fragmentation by MS/MS, enzymatic digest
sequencing and knowledge of the glycan biosynthetic
pathways [14].
As a drawback, MALDI-TOF MS analysis does not allow
distinguishing between isobaric glycans. Alternative strate-
gies, like ion-mobility MS or non-MS approaches such as
Normal Phase HPLC (NPLC) coupled to fluorescent labeling can
overcome this issue. Ideally a combination of both, MS and
non-MS approaches provide complete information regarding
glycosylation profiles. NPLC of fluorophore labeled glycans
gives great sensitivity and can be performed with a range of
chromatography phases to give orthogonal separations [10].
For NPLC the hydrophilic interaction liquid chromatography
(HILIC) mode is predominantly used to assign structures.
Relative scales are produced by running purified glycan stan-
dards and samples of interest are compared with standards'
chromatographic profiles. In addition, glycan databases are
available to compare and assign structures relative to reten-
tion times (RT). The most common fluorescent tags used are
2-aminobenzamide (2AB), 2-aminobenzoic acid (2AA) or
2-aminopyridine (2AP). Finally, capillary gel electrophoresis
with laser induced fluorescence (CGE–LIF) offers faster anal-
ysis times than NPLC, though currently no databases are
available to search mobility against structures, and data need
to be cross-correlated with either NPLC or MS approaches
when developing and validating methods [10]. In the current
approach we have focused on the application of NPLC and
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biosimilar mAbs of Trastuzumab.2. Materials and methods
2.1. Reagents
Ammonium hydrogen carbonate, sodium chloride, iodo-
acetic acid (IAA), DTT, α-cyano-4-hydroxycinnamic acid
(HCCA), and hexanes were purchased from Sigma-Aldrich.
Glacial acetic acid, acetonitrile, ammonia, chloroform,
DMSO, methanol, propan-1-ol, sodium hydroxide pellets
and TFA were from Romil. 2,5 dihydroxybenzoic acid (DHB)
was from Fluka. Methyl iodide was obtained from Alpha
Aesar. Tris(hydroxymethyl)-aminomethane was from Fish-
er. 3,4-diaminobenzophenone (DABP) was from Acros Or-
ganics. All aqueous solutions were prepared using ultrapure
(Milli-Q) water.
2.2. Preparation of mAb samples
Both IgG1 mAb biosimilars were obtained from two different
clones of human-derived cells and purified from the
harvested medium using a Protein A column. The final
products were obtained in solution form as mAb1 and
mAb2, both at 1 mg/ml in citrate–Tris pH 8. Trastuzumab
was obtained from providers (Herceptin®, Genentech, South
San Francisco, CA).
2.3. Oligosaccharide analysis by NPLC and
fluorescence detection
2.3.1. Sample preparation
An amount of 200 μg of mAbs were dissolved in 100 μl of 0.1%
Rapigest solution (2 mg/ml final solution), reduced with
45 mM DTT, 30 min at 60 °C, and alkylated with 10 mM IAA,
20 min, room Tª in the darkness, in 100 mM ammonium
bicarbonate (Ambic). Glycosylated IgGs were digested with
trypsin (Promega) (1:20) to reduce proteins to the peptide level
and finally N-linked glycans were released by digestion with
Peptide -N-Glycosidase F (PNGaseF, New England BioLabs)
(1:25), 18 h, 37 °C. Following digestion, acetonitrile was
added up to 90% and N-glycans were purified using HILIC
microelution SPE in a 96-well format (Waters, Milford, MA,
USA) according to manufacturer's guidelines. Briefly, sam-
ples were washed several times with 90% acetonitrile
and eluted with 1 mM ammonium Tris citrate in 10%
acetonitrile, fractions were combined and speed-vac dried.
Purified N-glycan samples were labeled with 2AB using a
GlycoProfile 2AB labeling Kit (Sigma, St. Louis, MO, USA) as
indicated by manufacturers. Finally, excess of fluorescent
2AB was removed using HILIC microelution plates as
described above.
2.3.2. HPLC fluorescence analysis
The 2AB labeled glycans (10 μg per sample) were further
analyzed by NPLC using a HILIC column (XBridge Amide
column, 2.5 μm XP, 3 × 100 mm, Waters, Milford, MA, USA) at60 °C and detected by an HPLC fluorescence detector (Hitachi
LaChrom Elite®), using excitation (330 nm) and emission
(428 nm) wavelengths.
Separations were performed according to manufacturer's
recommendations, using 100 mM ammonium formate (pH 4.5)
as mobile phase A and 100% acetonitrile as mobile phase B. For
glycan elution, the HPLC gradient was carried out as follows:
after 45 min at 25% A and 75% B, flow rate 0.5 ml/min, the
gradient went to 40% A and 60% B for 1.5 min and then to 100%
A until minute 48, remaining at a flow rate of 0.2 ml/min for
two more minutes, returning to 25% A–75% B for a further
12 min. N-linked glycan structures were assigned to peaks
based on comparison to reference structures (2AB-labeled
human IgG N-glycans, Prozyme, San Leandro, CA). G0, G1, and
G2 refer to complex, neutral, biantennary structures with 0, 1,
or 2 terminal galactose residues, while G0F, G1F and G2F are the
corresponding core with fucosylated structures [15]. At least
three run replicates were obtained for both biosimilars mAb1
andmAb2, and for Trastuzumab. The relative abundance (RA%)
of each glycan in all three samples is expressed as the average
of the percentage of total peak area ± standard deviations
(RA ± SD). Intra-assay CVs% were calculated between repli-
cates for each glycan in all threemAbs. The RA% of the glycans
in the biosimilar mAbs were compared with those annotated
for Trastuzumab using two-tailed t-tests. In order to com-
pare the overall glycan profiles of the HPLC chromatograms,
RA% data profiles were compared using the Pearson prod-
uct–moment correlation coefficient.
2.4. Oligosaccharide analysis by MALDI-TOF MS
2.4.1. Sample preparation
100 μg of lyophilized and previously purified antibodies
was reduced with 500 μl DTT (2 mg/ml) in 0.6 M Tris buffer,
pH 8.5, 1 h, 37 °C and carboxymethylated with 500 μl
Iodoacetic acid (12 mg/ml) in 0.6 M Tris buffer, pH 8.5,
90 min, room temperature, in the dark. Samples were then
dialyzed 48 h at 4 °C in 50 mM Ambic and lyophilized prior to
digestion with 0.3 mg of trypsin (1 mg/ml) in 50 mM Ambic
at 37 °C, 16 h. Trypsin reaction was stopped by heating the
samples at 100 °C and finally with a few drops of 5% acetic
acid. Products were purified by SepPak C18 columns as des-
cribed [16], in order to separate glycopeptides from non-
glycopeptides.
Glycopeptides were concentrated by speed vac, lyophilized
and digested with 5 U of PNGase F 37 °C, 24 h, for glycans
release and separated from peptides by a SepPak C18 purifi-
cation using sequential elution with 20% and 40% propanol.
The glycan fraction was concentrated by speed vac and
lyophilized. Finally, N-glycans were permethylated with
NaOH as described [17]. Briefly, samples were dissolved in
500 μl of a NaOH/DMSO slurry and 500 μl of methyl iodide,
gently mixed for 20 min at room temperature. Permethylation
was quenched by the addition of a few drops of ice-cold water,
followed by pH neutralization to approximately pH 6.5 with
5% acetic acid.
Glycans were then extracted with chloroform and purified
with sequential fractions of acetonitrile by Sep-Pak C18.
Samples were concentrated in a SpeedVac, lyophilized,
diluted in 10 μl methanol and mixed 1:1 with a DHB matrix
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MALDI-TOF MS.
2.4.2. MALDI-TOF MS analysis
MALDI-TOF MS analysis was performed on a Voyager-DE sSTR
MALDI-TOF (PerSeptive Biosystems, Framingham, MA, USA)
in the reflectron mode with delayed extraction. The instru-
ment was calibrated externally using a standard mixture
containing des-Arg1-bradykinin (molecular mass 904.46 Da),
angiotensin I (molecular mass 1296.68 Da), human [Glu1]-
fibrinopeptide B (molecular mass 1570.67 Da), adrenocortico-
tropic hormone (ACTH)-(1–17) (molecular mass 2093.08 Da),
ACTH-(18–39) (molecular mass 2465.19 Da) and ACTH-(7–38)
(molecular mass 3657.92 Da).
Data were acquired using Voyager 5 Instrument Control
Software and were processed using Data Explorer MS
processing software from Applied Biosystems. Final spectra
were obtained as an average of 500 shots at different laser
irradiation positions. Two replicates were obtained per
sample. Further MS/MS analyses of peaks observed in the
MS spectra were carried out using a 4800 MALDI-TOF/TOF
(Applied Biosystems) mass spectrometer. The potential
difference between the source acceleration voltage and the
collision cell was set to 1 kV, and argon was used as collision
gas. The 4700 calibration standard kit, calmix (Applied Bio-
systems), was used as the external calibrant for the MS
mode, and [Glu1] fibrinopeptide B human (Sigma) was used
as an external calibrant for the MS/MS mode. MALDI spectra
were further analyzed using the GlycoWorkbench software
suite [18] which allowed assigning glycan masses to the
corresponding oligosaccharide structures.3. Results
3.1. N-linked glycosylation profile of mAb biosimilars by HPLC
analysis coupled to fluorescence detection
N-linked glycans from mAb1, mAb2 and Trastuzumab were
released with PNGase F and fluorescently labeled with 2AB
prior to HILIC separation coupled to NPLC analysis. Resultant
N-glycan profiles are shown in Fig. 1 whereas RT and
abundance (RA%) of each glycan isoform have been included
in Table 1. Four major peaks were observed in the chromato-
gram of the three mAbs: G0F, G1Fa, G1Fb and G2F, repre-
senting 90% of the total glycan population. G1Fa and G1Fb,
two isomeric glycans with the same molecular weight but
different oligosaccharide structural distribution, appeared in
the chromatogram at different RT (12.27 ± 0.08 and 12.86 ±
0.08 min respectively). Relative quantification of glycan abun-
dance was also carried out, allowing us to compare between
the tested mAbs (Table 1). Thus, while Trastuzumab and
mAb2 shared the same pattern of G0F > G1Fa > G1Fb > G2F,
the profile seen for mAb1 was different for the most abundant
glycans: G1Fa > G0F > G2F > G1Fb. The rest of the oligosac-
charides seen represented less than 10% of the total glycan
population. Finally, although not abundant (<6.5% in total for
all cases detected), some sialic residues were found in the
mAbs (indicated as sial in Table 1, i.e. G1Fa_sia), barelydetected in Trastuzumab (<1% in total). In general CV% values
were lower than 10% but for the less abundant glycans such as
the sialylated ones, CV% could reach 35%.
When samples were compared between themselves, RA%
was quite different between those seen in the biosimilar
mAbs and Trastuzumab, with p-values <0.01 in most cases
(Table 1). Comparison of the glycan profiles of the three mAbs
using the Pearson product–moment correlation coefficient
indicated that the overall glycan profile of the mAb2 (0.995)
was closer to Trastuzumab thanmAb1 was to the later (0.965).
3.2. N-linked glycosylation profile by MALDI-TOF MS analysis
MALDI-TOF MS analysis of derivatized glycans provided
spectra for mAb1 and mAb2 (Fig. 2), with masses correlating
to G0F, G1F, and G2F as the most abundant oligosaccharides
(see Fig. 3 for glycan nomenclature, molecular weight and
correlation with the biantennary structure). The MS spectrum
of the glycans linked to Trastuzumab has not being included
for simplicity, but it presented the same peaks seen with both
mAbs (data not shown). Although MALDI-TOF MS analysis
wasmostly used to confirm the molecular structures detected
by NPLC, the peak intensities from the permethylated glycans
indicated a relative abundance similar to the variations seen
by liquid chromatography, in agreement with previous
reports [19]. Thus, at least for the most abundant glycans,
the relative abundance in MALDI (considering peak intensi-
ties) and in the NPLC approach (based on fluorescence
intensities) appeared as follows: G1F > G0F > G2F in the
mAb1 and G0F > G1F > G2F in the mAb2. We could not
distinguish between different isoforms of G1F (G1Fa and
G1Fb), sharing the same molecular weight. Finally, small
signals corresponding to bi- and tri-antennary sialylated
glycan residues of m/z: 2401 Da (G1F + sial), 2431 Da
(G2 + sial), 2605 Da (G2F + sial) and 3054 Da (triantennary
fucosylated with one sialic acid) were detected in the MALDI
analysis of the sample mAb2 (not shown in the spectra), but
not in the mAb1. This is most likely due to loss of sialic acid
during sample handling, as permethylated sialylated glycans
are very stable on MALDI and can be observed at very high
sensitivity as previously demonstrated [20].
Tandem MS/MS spectra were acquired for some of the
glycans detected (i.e. for m/z: 1386.92, 2040.02, or m/z:
2244.14 Da). Fig. 4 includes an example of MS/MS fragmenta-
tion for the glycan G2F (m/z: 2244.14 Da). Structural assign-
ment in both, MS and tandem MS/MS analysis was performed
using the GlycoWorkbench suite [18].4. Discussion
In the current work, we applied two alternative but com-
plementary strategies to analyze the N-glycomic profile of
two purified mAbs tested as biosimilar candidates for
Trastuzumab: NPLC coupled to glycan fluorescent labeling
and MALDI-TOF MS. Both methodologies included a first step
of enzymatic N-glycan releasing under non-denaturing con-
ditions [13,14] previous to tryptic digestion in order to reduce
protein complexity down to the peptide level. This reduction
Fig. 1 – N-linked glycan profiles obtained by HPLC analysis from Trastuzumab, mAb1 and mAb2. Glycan assignments were
done by comparison with commercially available standards.
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cleave off the intact glycan from the protein side of the
antibodies.
Separation and detection of 2AB-labeled glycans by NPLC
allowed identifying almost 100% of the glycan composition in
both mAb candidates, including four major glycans (G0, G1Fa,
G1Fb and G2F) and 21 minor ones, but no less important
oligosaccharides. The identification was done by comparingthe elution patterns of the analyzed mAb glycans with
commercially available glycan standards. We also distin-
guished between different isobaric structures, such as G1Fa
and G1Fb, due to the slight difference in their respective RT. In
the MALDI-TOF MS approach, the most intense peaks
correlated to the major glycans (G0, G1 and G2) and several
less abundant oligosaccharides were also identified, based
purely on the mass of the different carbohydrates, with no
Table 1 – Percentage of glycan composition from Trastuzumab and mAbs. The retention times (RT) are given in minutes as
an average of the RT seen in the three samples, Trastuzumab, mAb1 and mAb2, with CV% values below 5% in both inter-
and intra-assays for the RT detected. The relative abundance (RA%) of each glycan isoform is shown as the calculated area
% ± sd. CV% is given for each isoform for all threemAbs (calculated from the RA%). The p-values were calculated to compare
between the RA% of Trastuzumab and the biosimilar candidates (Trastuz vs mAb1 and Trast–mAb2). Samples were run in
triplicates. N-acetylglucosamine (Nacg); sialic acid (sial); Mannose (Man).
RT (min)
(average ± SD)




RA% CV% RA% CV% RA% CV%
6.93 ± 0.04 0,65 ± 0.05 7.24 0.25 ± 0.01 2.36 0.44 ± 0.03 6.03 0.001 0.007
7.31 ± 0.04 3.62 ± 0.01 0.16 0.22 ± 0.02 7.03 0.54 ± 0.04 6.91 <0.001 <0.001
8.83 ± 0.05 37.73 ± 0.14 0.37 31.68 ± 0.40 3.46 43.61 ± 1.28 5.92 <0.001 0.012
9.89 ± 0.05 1.02 ± 0.02 1.95 3.73 ± 0.11 2.89 1.10 ± 0.05 4.62 <0.001 0.118
10.37 ± 0.04 2.70 ± 0.03 1.28 0.82 ± 0.03 3.40 0.55 ± 0.03 4.96 <0.001 <0.001
10.89 ± 0.00 0.00 0.00 0.04 ± 0.00 7.25 <0.001 0.220
11.23 ± 0.65 0.76 ± 0.01 1.21 0.00 0.13 ± 0.01 5.38 <0.001 <0.001
11.48 ± 0.09 0.19 ± 0.00 0.37 0.19 ± 0.01 3.34 0.00 0.975 <0.001
12.27 ± 0.08 31.73 ± 0.15 0.46 37.40 ± 0.51 2.93 32.07 ± 0.74 6.13 <0.001 0.581
12.86 ± 0.08 10.90 ± 0.09 0.79 10.68 ± 0.17 3.08 10.95 ± 0.29 5.94 0.044 0.823
13.84 ± 0.13 0.11 ± 0.00 0.63 0.50 ± 0.03 6.51 0.33 ± 0.02 4.65 <0.001 <0.001
14.48 ± 0.21 0.25 ± 0.00 0.85 0.24 ± 0.01 5.83 0.21 ± 0.01 6.44 0.529 0.023
15.21 ± 0.45 0.65 ± 0.00 0.22 0.03 ± 0.00 4.00 0.00 <0.001 <0.001
16.22 ± 0.02 0.00 0.47 ± 0.02 4.22 0.48 ± 0.02 4.52 <0.001 <0.001
17.12 ± 0.11 6.36 ± 0.00 0.04 12.30 ± 0.30 3.18 6.46 ± 0.28 6.33 <0.001 0.003
18.31 ± 0.08 0.17 ± 0.01 8.57 0.15 ± 0.01 5.76 0.13 ± 0.02 13.22 0.217 0.124
19.47 ± 0.02 0.00 0.22 ± 0.01 2.48 0.09 ± 0.01 8.07 <0.001 <0.001
21.32 ± 0.01 0.00 0.08 ± 0.02 19.70 0.08 ± 0.01 12.29 0.006 0.002
21.63 ± 0.04 0.86 ± 0.03 3.37 0.08 ± 0.02 21.88 0.09 ± 0.01 12.38 <0.001 <0.001
23.25 ± 0.51 0.06 ± 0.00 34.57 0.02 ± 0.00 19.50 0.06 ± 0.01 21.65 <0.001 0.919
24.51 ± 1.05 0.05 ± 0.01 2.57 0.01 ± 0.00 28.47 0.03 ± 0.03 82.66 0.002 0.425
25.87 ± 0.04 0.00 0.14 ± 0.03 23.58 0.26 ± 0.03 11.83 0.011 <0.001
27.48 ± 0.98 0.34 ± 0.24 0.38 0.01 ± 0.00 10.10 0.03 ± 0.00 14.29 0.282 0.343









Fig. 2 – Full-scale MALDI-TOF MS spectra of mAb1 and mAb2 glycosylation sites. Structural assignments were based on
compositions assigned from molecular masses, complemented by MS/MS information. All molecular ions are [M + Na]+.
Structural assignments are based on monosaccharide composition, fragmentation analyses and knowledge of the glycan
biosynthetic pathways.
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Fig. 3 – Biantennary oligosaccharide structure of themajor glycans detected in the study. Sugar symbols are those employed by
the Consortium for Functional Glycomics (http://www.functionalglycomics.org).
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carried out with the support of the GlycoWorkbench suite
[18], a software that provides appropriate tools to rapidlyFig. 4 – MALDI TOF/TOF MS/MS spectrum of the permethylated N
of the mAb1. Assignments of the fragment ions generated are shassemble and match structure models with MS data and
compared to diverse glycan databases to assess the best
candidate for the m/z evaluated. In contrast to the NPLC-glycan at m/z 2244.14 Da, derived from the glycan spectrum
own.
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between isoforms sharing the same molecular weight, al-
though other complementary strategies could be employed in
order to elucidate these structures, including further enzy-
matic treatment and/or linkage analysis [13]. Finally, the use
of 2AB standards in the NPLC approach, and glycan derivati-
zation by permethylation prior to MALDI-TOF MS, significant-
ly helped to detect the less abundant oligosaccharides,
including different sialylated forms (comprising less than 2%
each one).
Sialylated glycans are usually difficult to analyze by
MALDI-TOF MS and they can easily lose a significant amount
of sialic acid in the ion source or after the ion extraction from
the ion source. To reduce this loss, sialylated glycans can be
analyzed in the linear negative ion mode, which however
means that neutral glycans cannot be detected at the same
time [13]. In the current approach we used permethylation as
derivatization strategy, which stabilizes the negative charge
of sialic residues by converting them to methyl esters, thus
preventing sialic acid loss while significantly improving the
efficiency of positive ion formation [19], allowing us to
simultaneously analyze neutral and sialylated oligosaccha-
rides in the ion positive mode.
Permethylation also prevents salt formation, which could
complicate the mass spectrum and impair the signal-to-noice
ratio for the individual molecular ion species. Furthermore,
permethylated oligosaccharides become resistant to in-
source fragmentation because of the lack of hydroxyl groups
which prevents the cleavage of other glycosidic bonds [21].
Herein, small signals corresponding to bi- and tri-antennary
sialylated glycan residues were detected in both, NPLC and
MALDI-TOF MS approaches (G1F_sial, G2_sial, G2F_sial).
Relative quantification in the NPLC 2AB-fluorescent ap-
proach was achieved by comparing, once again, glycan
intensities with already known glycan standards. Chromatog-
raphy of reductively aminated oligosaccharides is generally
accepted as a standard method of quantitation, in which the
fluorescence correlates with the amounts of individual
components [19]. The data presented in Table 1 correspond
to the relative abundances of each glycans presented as an
average ± sd of three independent runs per sample, the mAb
biosimilar candidates and Trastuzumab, confirming that the
most abundant glycans were the fucosylated species G0F,
G1Fa, G1Fb and G2F. CV% values of relative abundances for
intra-assays were lower than 10% in most cases, only higher
than 20% in the less abundant glycans such as the sialylated
ones. Comparison of both mAb candidates with Trastuzumab
indicated that the RA% was not similar to the innovator
(p < 0.01), although the overall glycan profile of mAb2 was
closer to the one seen for Trastuzumab than the glycan profile
of mAb1.
Although we initially used MALDI-TOF MS to confirm the
molecular structure seen by the NPLC approach by mass
assignment, we found that relative peak intensities detected
in the glycan spectra were correlated, at least in the most
abundant oligosaccharides (G0F, G1F and G2F), with the
relative abundances seen by 2AB-LC. It is generally accepted
that MS does not allow real quantitation for oligosaccharides
unless stable isotope-labeled analogs are incorporated as
internal standards [19]. Despite this assumption, severalstudies have demonstrated that MALDI-TOF MS analyses of
permethylated glycans provide reliable relative quantitation
information based on signal intensities, particularly when
comparisons are made over a small mass range of single ion
peaks in the same spectrum [19]. Therefore, even though we
decided to take the quantitative data from the NPLC analysis,
a more exhaustive processing of the MALDI data could have
been done with the permethylated glycans, by measuring the
peak height of the monoisotopic ions [M + Na]+ or the
integrated peak area for the entire isotopic cluster to obtain
a more accurate relative quantitation.
Overall, comprehensive glycosylation profiling confirmed
that the proportion of individual glycans was different
between the biosimilars and the innovator, although the
number and identity of glycans were the same. Our data
indicated that at least in the mAbs analyzed, an optimization
of the production parameters (i.e. cell growing conditions)
appear to be necessary in order to deliver consistent and
appropriate glycosylation profiles closer to the innovative
drug Trastuzumab. The next logical step, which goes beyond
the limits of this work, would be to understand the biological
consequences of the glycosylation profiles identified in both
biosimilar candidates. Nevertheless, in terms of glycan
analysis, both methodological processes described here pro-
vided an excellent performance in glycan separation from the
protein antibody fraction, delivering quite clean glycan
profiles and no cross contamination with the Fc region of
the mAbs.5. Conclusions
In this study, we have identified the most and the less
abundant N-glycans in two mAbs tested as biosimilar
candidates for Trastuzumab. Both methods, NPLC coupled to
fluorescence detection and MALDI-TOF MS analysis of
permethylated oligosaccharides, have allowed us to identify
and confirm the presence of individual glycan molecules, by
using standards or by specific mass assignment. In addition,
an estimation of the glycan percentage into these antibodies
was seen in the NPLC method. In summary, both strategies
described herein have provided complementary and support-
ive data of the N-glycan composition of the mAbs tested, and
therefore could be considered as routine methods for the
characterization of glycan profiles of recombinant mAbs.Transparency document
The Transparency document associated with this article can
be found, in the online version.Acknowledgments
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